Palazestrant efficacy and safety
4 evidence topics · 16 sources
Summary: development status and pivotal trial design (OPERA-01)
- Palazestrant is an investigational oral complete estrogen receptor antagonist and selective estrogen receptor degrader. The sponsor has no product approved for commercial sale. In July 2022, FDA granted Fast Track designation for ER+/HER2- metastatic breast cancer that has progressed following one or more lines of endocrine therapy with at least one line given in combination with a CDK4/6 inhibitor.
- OPERA-01 (NCT06016738) is a global phase 3, randomized, open-label, active-controlled trial in men and women aged 18 years or older with ER+/HER2- locally advanced or metastatic breast cancer that progressed after endocrine therapy combined with a CDK4/6 inhibitor. One additional line of endocrine monotherapy is allowed, and participants who received chemotherapy in the advanced or metastatic setting, or prior elacestrant or an investigational estrogen receptor-directed therapy, are excluded.
- In Part 1 (dose selection), approximately 120 participants were randomized 1:1:1 to palazestrant 90 mg or 120 mg once daily or standard-of-care endocrine therapy. The independent data monitoring committee recommended 90 mg, and the sponsor aligned with FDA on 90 mg as the Part 2 dose. In Part 2, participants are randomized 1:1 to palazestrant 90 mg once daily or the investigator's choice of fulvestrant or an aromatase inhibitor (letrozole, anastrozole, or exemestane). Randomization is stratified by ESR1 mutation status in circulating tumor DNA, prior lines of endocrine therapy for advanced disease (1 vs 2), and visceral disease.
- The dual primary endpoint is PFS assessed by blinded independent central review, analyzed separately in participants with ESR1-mutated tumors and in participants without detectable ESR1 mutations; overall survival in the same two populations is a key secondary endpoint. Approximately 510 participants are planned, including 470 for the primary analysis. OPERA-01 participants receive a tablet formulation, whereas the phase 1/2 monotherapy data were obtained with capsules.
- Enrollment began in November 2023 and is complete. No OPERA-01 efficacy or safety results have been reported. The sponsor anticipates top-line results in the first quarter of 2027, an NDA submission in 2027, and, if the trial is successful, potential FDA approval and commercial launch in 2028.
- A second phase 3 trial, OPERA-02 (NCT07085767), compares palazestrant with ribociclib against letrozole with ribociclib in approximately 1,000 participants who have not received prior systemic treatment for advanced breast cancer, a population outside this indication. Top-line data are anticipated in 2028.
Summary: monotherapy efficacy (OP-1250-001)
- OP-1250-001 (NCT04505826) was an open-label, multicenter, phase 1/2 study of single-agent palazestrant capsules taken once daily in the fasted state by participants with previously treated ER+/HER2- advanced or metastatic breast cancer. The peer-reviewed publication includes 146 participants enrolled at 15 sites in the US and Australia between August 2020 and November 2022, with a data cutoff of July 7, 2023. The study had no comparator arm.
- During dose escalation, 42 participants received 30 to 300 mg/day; there were no dose-limiting toxicities, and the maximum tolerated dose was not reached. Exposure was dose-proportional from 30 to 300 mg/day, the effective half-life was approximately 70 h, and the terminal half-life was approximately 8 days. Doses of 60 and 120 mg/day were carried into dose expansion, and 120 mg/day was selected as the recommended phase 2 dose on the basis of a clinical benefit rate (CBR) of 46% at 120 mg/day and 19% at 60 mg/day.
- Of the 116 participants treated at 60 or 120 mg/day, 95.7% had received a prior CDK4/6 inhibitor, 63.8% had received at least 2 prior lines of endocrine therapy in the advanced setting, and 51 of 96 with baseline circulating tumor DNA results (53.1%) had ESR1 mutations.
- In the peer-reviewed publication, the 120 mg/day cohort (n = 86) had 3 confirmed partial responses (4.5%) and 2 unconfirmed partial responses (3.0%) among 66 response-evaluable participants, with one further confirmed partial response after the data cutoff (4 confirmed, 6.0%). The CBR was 45.7% (95% CI, 33.7 to 58.1) among 70 CBR-evaluable participants and 58.6% (95% CI, 38.9 to 76.5) among 29 CBR-evaluable participants with ESR1 mutations. Median PFS was 4.8 months (95% CI, 3.5 to 7.1) with a 6-month PFS rate of 39%; in participants with ESR1 mutations, median PFS was 5.6 months (95% CI, 4.8 to not estimable) with a 6-month PFS rate of 47%. In total, 32 of 86 participants (37.2%) remained on treatment for 6 months or longer. In the 60 mg/day cohort, the CBR was 19.2% (95% CI, 6.6 to 39.4) among 26 evaluable participants.
- The 2023 conference presentation reports different values for the 120 mg cohort: a CBR of 40% (32/81) in all participants, 52% (17/33) with ESR1 mutations, and 32% (12/38) with ESR1 wild-type tumors, and a median PFS of 4.6 months (95% CI, 3.5 to 6.5) with a 6-month PFS rate of 38% in all 86 participants. The 2023 company announcement reports a median PFS of 3.5 months in participants with ESR1 wild-type tumors.
- In a subset analysis of 49 participants who received palazestrant as second- or third-line therapy with or without prior chemotherapy, median PFS was 7.2 months and the CBR was 48%; among participants in this subset with ESR1 mutations, median PFS was 7.3 months and the CBR was 59%.
Summary: combination efficacy (OP-1250-003 and OP-1250-002)
- OP-1250-003 (NCT05508906) is a phase 1b, open-label, 2-part study of palazestrant with ribociclib, alpelisib, everolimus, or atirmociclib. The ribociclib group allowed up to 2 prior endocrine therapies with or without a CDK4/6 inhibitor and up to 1 prior line of chemotherapy for advanced disease. At the July 8, 2025 data cutoff, 78 participants were enrolled in the ribociclib group and data were presented for 72: 56 received palazestrant 120 mg and 16 received 90 mg, all with ribociclib 600 mg. Of the 72, 24 (33%) had no prior line of therapy in the advanced setting, 45 (63%) had received a prior CDK4/6 inhibitor with endocrine therapy for advanced disease, and 15 of 69 (22%) had ESR1 mutations at baseline.
- In the 120 mg cohort, median PFS was 15.5 months in all participants, 12.2 months in participants with a prior CDK4/6 inhibitor, 9.2 months in those with ESR1 wild-type tumors and a prior CDK4/6 inhibitor, and 13.8 months in those with ESR1-mutated tumors and a prior CDK4/6 inhibitor; median follow-up was 19.1 months in all participants and 19.8 months in those with a prior CDK4/6 inhibitor. In the 90 mg cohort, median follow-up was 10.8 months and median PFS was not reached.
- Among response-evaluable participants with measurable disease, the objective response rate was 34% (15/44) overall, 31% (10/32) in the 120 mg cohort, 26% (6/23) in participants with a prior CDK4/6 inhibitor in the 120 mg cohort, and 42% (5/12) in the 90 mg cohort. Ribociclib had no clinically meaningful effect on palazestrant exposure, palazestrant had no clinically meaningful effect on ribociclib exposure, and exposure did not differ to a clinically significant degree between the 90 mg and 120 mg doses. Initial data from the atirmociclib group are expected in December 2026.
- OP-1250-002 (NCT05266105) is an open-label, phase 1b dose-escalation and dose-expansion study of palazestrant with palbociclib 125 mg once daily on days 1 to 21 of each 28-day cycle, in participants with zero or one prior endocrine therapy with or without a CDK4/6 inhibitor for advanced disease. At the September 15, 2023 data cutoff, 46 participants were enrolled (37 at palazestrant 120 mg), and 33 (72%) had received a prior CDK4/6 inhibitor for advanced disease. Partial responses were observed in 7 participants (2 confirmed and 5 unconfirmed). The CBR was 46% (12/26) in all participants and 60% (6/10) in participants with ESR1 mutations; the company announcement reports a CBR of 71% in participants without prior CDK4/6 inhibitor treatment. Palbociclib 125 mg did not affect palazestrant exposure, and palazestrant did not affect palbociclib exposure.
Summary: safety
- Monotherapy (OP-1250-001, peer-reviewed publication, 120 mg/day, n = 86): 95.3% of participants had at least one treatment-emergent adverse event (TEAE), most commonly nausea (62.8%), vomiting (29.1%), and fatigue (25.6%). Grade 3 TEAEs occurred in 21 participants (24.4%) and grade 4 TEAEs in 8 (9.3%), including neutropenia in 6. Grade 3 treatment-related adverse events occurred in 10 participants (11.6%), and treatment-related grade 4 neutropenia in 5 (5.8%). Treatment-related diarrhea of any grade occurred in 13%, with no grade 3 or higher events.
- Grade 4 neutropenia: the publication states that the events occurred approximately 6 to 8 weeks after initiation, and the 2023 company announcement states approximately 4 to 6 weeks into therapy and that all 6 affected participants had prior CDK4/6 inhibitor exposure. In 3 of the 6, neutropenia resolved with a 1-week interruption followed by dose reduction, and in 3 it resolved after discontinuation. Ongoing studies monitor blood counts more frequently during the first 6 to 8 weeks of treatment.
- Bradycardia (9%) and photopsia (5%) occurred at 120 mg/day; all events were grade 1 and led to no dose modifications, interruptions, or discontinuations. No QTcF value exceeded 500 ms. Among the 116 participants treated at 60 or 120 mg/day, 7 (6.0%) discontinued treatment for adverse events. The publication states that fasted administration, the exclusion of proton pump inhibitors and most common antiemetics, and a relatively large capsule could each have contributed to gastrointestinal events; OPERA-01 uses a tablet formulation.
- The posted registry results list 83 participants at risk at 120 mg, with serious adverse events in 16 of 83 (19.28%), and serious febrile neutropenia in 2 of 83 (2.41%); aspartate aminotransferase increase was reported in 13 of 83 (15.66%).
- Combination with ribociclib (OP-1250-003, July 2025 data cutoff): treatment-related neutropenia occurred in 47 of 56 participants (84%) at palazestrant 120 mg, grade 3 in 28 (50%) and grade 4 in 5 (9%), and in 13 of 16 (81%) at 90 mg, grade 3 in 9 (56%). Treatment-related QT prolongation on electrocardiogram occurred in 16 (29%) and 4 (25%), respectively. Two participants had dose reductions of palazestrant only, 8 of both drugs, and 23 of ribociclib only, most often for neutropenia. Three participants discontinued both drugs for a TEAE. Two participants had grade 5 adverse events, neither related to palazestrant.
- Combination with palbociclib (OP-1250-002, September 2023 data cutoff, N = 46): neutropenia occurred in 40 participants (87%), grade 3 in 28 (61%) and grade 4 in 5 (11%), and nausea in 26 (57%). No participant had a palazestrant dose reduction for neutropenia, 11 had palbociclib dose reductions for neutropenia, and 1 discontinued both drugs for nausea concurrent with disease progression.